Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oftac
- Development stage
- Phase 2
- Lead developer
- BioNanoSim
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Oftac is a preservative-free, topical ophthalmic nano-emulsion of tacrolimus (0.05%) developed by BNS Ophthalmics, a joint venture between BioNanoSim and RAFARM, for the treatment of active non-infectious anterior uveitis. Tacrolimus is a potent immunosuppressive calcineurin inhibitor that is highly insoluble and unstable in water. Oftac utilizes BioNanoSim's proprietary nano-emulsion technology, which encapsulates tacrolimus within the oil core of nano-scale oil droplets (mean size under 200 nm) dispersed in water. This formulation enhances the drug's stability, bioavailability, and corneal penetration, allowing for effective local delivery to ocular tissues with minimal systemic exposure. Oftac has completed a Phase 1/2a clinical trial in Israel and has received orphan drug designation from the US FDA for the treatment of uveitis.
- Brand names
- Oftac
- Other names
- tacrolimus nano-emulsion eye dropstacrolimus ophthalmic emulsion
02
Targets
FKBP1A
Beyond the preview
Go deeper on Oftac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oftac.